Telix Pharmaceuticals Limited’s EV / EBITDA at a glance
Telix Pharmaceuticals Limited reports ev / ebitda of 86.7x for Dec 2024. The prior period recorded 135.5x (Dec 2023). Year over year the metric moved −48.8 (−36%). The rolling three-period average stands at 66.3x. Data last refreshed Dec 7, 2025, 2:47 AM.
Latest reading
86.7x · Dec 2024
YoY movement
−48.8 (−36%)
Rolling average
66.3x
Current EV / EBITDA
86.7x
−48.8
−36%
Rolling average
66.3x
Latest Value
86.7x
Dec 2024
YoY Change
−48.8
Absolute
YoY Change %
−36%
Rate of change
3-Period Avg
66.3x
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s ev / ebitda stands at 86.7x for Dec 2024. Year-over-year, the metric shifted by −48.8, translating into a −36% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How ev / ebitda shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports ev / ebitda of 86.7x. Use EV/EBITDA to benchmark acquisition multiples, leverage-adjusted valuation, and comparable transaction ranges.
Why EV/EBITDA matters
It normalizes valuation across different leverage levels, making it a go-to metric for M&A and cross-company comparisons.
Watch for cyclical swings
EBITDA can swing with cycle-sensitive businesses. Track multi-year averages and peak vs. trough to understand value ranges.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s ev / ebitda profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current ev / ebitda?
As of Dec 2024, Telix Pharmaceuticals Limited reports ev / ebitda of 86.7x. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's ev / ebitda trending year over year?
Year-over-year, the figure shifts by −48.8 (−36%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does ev / ebitda matter for Telix Pharmaceuticals Limited?
The enterprise value to EBITDA ratio evaluates valuation relative to operating cash flow before capital structure impacts. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's ev / ebitda above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 66.3x. Comparing the latest reading of 86.7x to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's ev / ebitda refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:47 AM and updates automatically every 24 hours, keeping your valuation inputs current.